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Abstract
Increased inflammation in the cerebral meninges is associated with extensive subpial 
cortical grey matter pathology in the forebrain and a more severe disease course in 
a substantial proportion of secondary progressive multiple sclerosis (SPMS) cases. 
It is not known whether this relationship extends to spinal cord pathology. We as-
sessed the contribution of meningeal and parenchymal immune infiltrates to spinal 
cord pathology in SPMS cases characterized in the presence (F+) or absence (F−) 
of lymphoid-like structures in the forebrain meninges. Transverse cryosections of 
cervical, thoracic and lumbar cord of 22 SPMS and five control cases were analyzed 
for CD20+ B cells, CD4+ and CD8+ T cells, microglia/macrophages (IBA-1+), 
demyelination (myelin oligodendrocyte glycoprotein+) and axon density (neurofila-
ment-H+). Lymphoid-like structures containing follicular dendritic cell networks and 
dividing B cells were seen in the spinal meninges of 3 out of 11 F+  SPMS cases. 
CD4+ and CD20+ cell counts were increased in F+  SPMS compared to F−  SPMS 
and controls, whilst axon loss was greatest in motor and sensory tracts of the 
F+  SPMS cases (P  <  0.01). The density of CD20+ B cells of the spinal leptome-
ninges correlated with CD4+ T cells and total B and T cells of the meninges; with 
the density of white matter perivascular CD20+ and CD4+ lymphocytes (P < 0.05); 
with white matter lesion area (P  <  0.05); and the extent of axon loss (P  <  0.05) 
in F+  SPMS cases only. We show that the presence of lymphoid-like structures in 
the forebrain is associated with a profound spinal cord pathology and local B cell 
rich meningeal inflammation associates with the extent of cord pathology. Our work 
supports a principal role for B cells in sustaining inflammation and tissue injury 
throughout the CNS in the progressive disease stage.
INTRODUCTION
Multiple sclerosis (MS) is a demyelinating and neurodegen-
erative disease of the brain and spinal cord characterized 
by adaptive and innate immune system activation and a 
profound accumulation of irreversible neurological disability. 
Monoclonal antibody therapies targeting the B cell antigen 
CD20 are beneficial in the early relapsing-remitting stage 
and in active primary progressive (PPMS) patients, highlight-
ing the prominent role B cells play in the disease process 
(23,29,43,45). Aggregates of B lymphocytes, which sometimes 
resemble ectopic B cell rich lymphoid-like structures, are 
seen in the forebrain leptomeninges in early (acute and 
relapsing-remitting MS) and late disease (secondary progres-
sive MS; SPMS) and closely associated with the sites of 
underlying demyelination, microglia/macrophage activation and 
neurodegeneration (6,22,25,35,40,49). It is unclear if lymphoid-
like structures exist in other leptomeningeal compartments 
and if they ever form adjacent to sites of white matter 
pathology. Given the critical involvement of the pathology 
of the spinal cord to the diagnosis and prognosis of MS, 
we thought it pertinent to explore these questions further.
Demyelination is extensive in the white and grey matter 
of the spinal cord (19). The extent of demyelination in 
part reflects atrophy of the cord and both whole cord and 
grey matter-specific measures of atrophy correlate with clini-
cal disease severity. Neurodegeneration in the cord undoubt-
edly contributes to both motor and sensory disability 
(19,33,48) and there is widespread synaptic, neuronal and 
axonal loss (14,16,20,52,57), which is seen in acute MS and 
could be the result of both local and distal pathological 
events (20,48,52).
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Leptomeningeal inflammation, characterized by increased 
numbers of circulating and long-lived B cells, plasma cells 
and large numbers of CD4+ and CD8+ T cells, is seen in 
a substantial proportion of MS cases, where it may play 
an important role in initiating and/or modulating demyeli-
nating pathology (10). Clones of related B cells are shared 
between pathological sites in the brain (34) and are efficiently 
able to activate T cells and myeloid cells, and act as antigen-
presenting cells (29). Subsets of memory B cells are a source 
of soluble inflammatory mediators, which are toxic to neu-
rons and oligodendrocytes in vitro (31,32). Studies focussed 
on the spinal cord have shown a prominent inflammation 
of the surrounding meninges, which is related to the extent 
of forebrain inflammation (58), whereby T cell infiltrates 
associate with parenchymal inflammation, demyelination and 
diffuse axonal loss (2,12). However, the contribution of 
B cells to spinal cord pathology has hitherto not been 
assessed in detail.
Our previous work has shown an involvement of menin-
geal inflammation, in particular the formation of ectopic 
lymphoid-like structures in the sulci, in the pathogenesis of 
cerebral and cerebellar cortical grey matter lesions in patients 
with acute and chronic progressive MS. Approximately 40% 
of all cases of SPMS harbored at least one (some with 
many) detectable lymphoid-like structure in their forebrain 
meninges (6,11,24,39-40,54). These findings support the 
hypothesis that meningeal inflammation gives rise to an 
increased inflammatory milieu in the CSF space, in particular 
the subarachnoid space, which might in part drive the for-
mation of grey matter lesions and an accompanying increased 
severity of clinical disease in some patients (38). The cyto-
toxic inflammatory milieu gives rise to alterations to the 
glial limitans and subsequent activation of microglia and 
neurodegeneration (18,39). Whether the same pathogenetic 
mechanisms may be operating in the spinal cord and con-
tribute to the more severe pathology in cases that exhibit 
ectopic lymphoid-like structures is unknown.
The aim of this study was to investigate the detailed 
cellular immunopathology of the spinal cord and meninges 
from cases of SPMS already characterized in terms of the 
presence or absence of detectable lymphoid-like structures 
in the forebrain leptomeninges. This work gives an insight 
into the CNS-wide extent of compartmentalized inflamma-
tion and diffuse meningeal infiltrates seen in some cases of 
SPMS, whilst confirming a key association between meningeal 
CD20+ B cells and the underlying demyelinating and neu-
rodegenerative pathology.
MATERIALS AND METHODS
Tissue samples
Post-mortem spinal cord tissue blocks from 22 cases of 
SPMS and from five non-neurological control cases were 
provided by the UK MS Tissue Bank at Imperial College. 
No cases of neuromyelitis optica were included in this study. 
All tissues were collected with fully informed consent via 
a prospective donor scheme with ethical approval by the 
National Research Ethics Committee (08/MRE09/31). 
Relevant clinical and demographic data are shown in Table 1 
and included information on the number and date of spinal 
relapses. All tissue blocks were paraformaldehyde fixed (mean 
fixation time  =  17  ±  6  days), cryoprotected in sucrose solu-
tion and frozen in isopentane on a bed of dry ice. Transverse 
sections of 10µm thickness were cut on a cryostat and 
stored at −80°C until required. To better understand the 
relationship between meningeal lymphoid-like structures and 
the extent of the spinal cord pathology, we analyzed the 
blocks of spinal cord from cases previously analyzed in 
work describing meningeal inflammation and forebrain 
pathology (24,39). We examined sections from three spinal 
cord tissue blocks (taken at the level of the cervical, tho-
racic and lumbar cord) per case, from 11 SPMS cases with 
lymphoid-like structures in the cerebral meninges (F+ SPMS), 
and 11 cases without detectable lymphoid-like structures 
(F−  SPMS; Table  1).
Immunohistochemistry
Sections were air-dried, rehydrated in phosphate-buffered 
saline (PBS, Sigma UK), and subjected to heat-induced 
antigen retrieval as indicated (Table  2). Endogenous per-
oxidase activity was quenched with a solution of PBS/0.3% 
(v/v) H2O2 and non-specific binding blocked by the addition 
of 10% normal sera in PBS. Primary antibodies (Table  2) 
were prepared in PBS, 0.2% Triton X-100 and 1% normal 
sera, and added to slides for an overnight incubation at 
4 °C. Bound primary antibody was detected by a two-step 
procedure by first incubating with an appropriate biotinylated 
secondary antibody (Vector Labs, UK) followed by the addi-
tion of the avidin-biotin horseradish peroxidase complex 
(ABC VECTASTAIN Elite kit; Vector) and 3,3′-diamin-
obenzidine (DAB) (IMMPACT DAB, Vector) as chromogen. 
Negative controls were included in each experiment and all 
sections from all cases were stained together in the same 
experimental run. Sections were counterstained in 
Haematoxylin, dehydrated, cleared in xylene and coverslipped 
in Depex Polystyrene (DPX; Sigma).
Immunofluorescence
Cryosections, prepared as above, were sequentially immu-
nolabeled using different antibodies in combination (listed 
in Table  2). Bound primary antibody was detected using 
appropriate Cyanine 3 (Cy3)-conjugated anti-mouse IgG 
(1:500) and Alexa Fluor-488-conjugated anti-rabbit IgG 
(1:500; Thermo Fisher, UK). All sections were counterstained 
with 4′,6-diamidino-2-phenylindole (1:5000, DAPI, Sigma) 
and aqueous mounted in VECTASHIELD Aq (Vector).
Quantification of demyelination
In order to determine the degree of demyelination in the 
spinal cord (n  =  11 F+ and 11 F−  SPMS), one section 
for each tissue block at each level was immunostained for 
myelin oligodendrocyte glycoprotein (MOG). Sections were 
scanned at 40x magnification using a Nikon Eclipse 80i 
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Table 1. Clinical information of multiple sclerosis and control cases.
Case Age at death Sex Disease duration Age at Onset
Spinal 
relapse (Y/N) PMD (hours) Cause of death
F+ blocks/total 
forebrain blocks
F+ SPMS
MS46 40 M 23 17 Y 18 Multiple sclerosis 3/11
MS79 49 F 24 25 ? 7 Bronchopneumonia 5/12
MS85 59 F 35 24 ? 27 Cerebrovascular Accident 2/11
MS92 37 F 17 20 N 26 Multiple sclerosis 7/12
MS154 34 F 11 22 Y 12 Pneumonia 4/12
MS160 44 F 16 28 Y 18 Bronchopneumonia 4/12
MS234 39 F 39 24 Y 15 Pneumonia 4/12
MS256 53 F 24 29 Y 21 Aspiration pneumonia 2/11
MS317 48 F 29 19 Y 21 Aspiration pneumonia 5/16
MS330 59 F 39 20 Y 21 Pneumonia 7/22
MS342 35 F 5 30 N 9 Multiple sclerosis 2/14
F− SPMS
MS3 55 M 21 34 Y 44 Urinary tract infection 0
MS21 58 M 41 17 N 16 Urinary tract infection 0
MS71 78 F 42 36 Y 5 Carcinoma of the 
bronchus
0
MS74 64 F 28 36 Y 7 Bronchopneumonia 0
MS101 50 M 31 19 Y 24 Bronchopneumonia 0
MS104 53 M 11 42 Y 12 Urinary tract infection 0
MS114 52 F 15 37 N 12 Bronchopneumonia 0
MS127 51 M 23 28 N 21 Bronchopneumonia 0
MS139 62 F 22 40 Y 9 Bronchopneumonia 0
MS340 53 F 19 34 N 17 Sepsis 0
MS341 52 F 22 30 Y 8 Aspiration pneumonia 0
Control
C07 85 F N/A N/A N/A N/A Cancer of the oesophagus N/A
C09 84 F N/A N/A N/A N/A Cerebrovascular disease N/A
C32 88 M N/A N/A N/A N/A Prostate cancer N/A
C41 54 M N/A N/A N/A N/A Lung cancer N/A
C45 77 M N/A N/A N/A N/A Cardiopulmonary 
degeneration
N/A
Abbreviations: ?  =  not known; F−  SPMS  =  lymphoid-like structure negative secondary progressive multiple sclerosis. F+  blocks/total forebrain 
blocks = frequency of lymphoid-like structure positive blocks of total forebrain tissue blocks sampled [see Magliozzi et al (39) and Howell et al (24) for 
further information]. N/A = not applicable; F+ SPMS = lymphoid-like structure positive secondary progressive multiple sclerosis.
Table 2. Primary antibodies for immunohistochemistry/immunofluorescence.
Antigen Cell specificity Clone Source
CD20†,¶ B lymphocytes L26 ThermoFischer
CD35‡,¶ Follicular dendritic cells Ber/MAC/DRC Agilent Dako
CD8†,¶ Cytotoxic T cells Rabbit pc ThermoFisher
CD8†,¶ Cytotoxic T cells C8/144B Agilent Dako
CD4†,¶ T helper cells BC/1F6 Abcam
Ig-A, -G, -M (FITC conjugated)¶ Plasma cells Rabbit pc Agilent Dako
Ki67† Proliferating cells Rabbit polyclonal Novacastra Labs
MOG§ Myelin and oligodendrocytes Z12 in house
MBP§ Myelin basic protein Rabbit pc Agilent Dako
IBA-1 Microglia/macrophages Rabbit pc Fujifilm Wako
Neurofilament heavy chain Axons, dendrites RT97 Chemicon/Merckmillipore
Neurofilament heavy chain Neuron, axon, dendrite Smi32 Chemicon/Merckmillipore
Antigen, cellular target and clone (for monoclonal antibodies) of antibodies used in this study. Antigen retrieval procedures.
†Sodium citrate buffer pH 6.
‡Dako target retrieval solution pH 9.
§Permeabilization with cold methanol.
¶Fixation with cold acetone.
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microscope and the tiled images reconstructed using Image-
Pro Plus (Media Cybernetics. Inc, UK). The total and the 
demyelinated areas of each spinal cord section were manu-
ally outlined and measured using Image-Pro Plus software 
and expressed relative to total white matter and/or total 
grey matter coronal area in that section.
Quantification of lymphocytes
In order to analyze the distribution of B- and T-lymphocytes 
in the spinal cord, we manually counted (under 200x mag-
nification using a Leica DM2500 microscope) the number 
of anti- CD20+, CD4+ and CD8+ cells in the total spinal 
meninges, and total section white and grey matter perivas-
cular space and parenchyma, respectively, in triplicate sec-
tions representing the three spinal cord levels sampled, per 
SPMS and control case. Lymphocyte counts were exhaustively 
conducted across the total section (n  =  3), for each of the 
three anatomically matched sampled tissues, per case. Total 
counts per region of interest per section were recorded as 
the focal nature of the infiltrates and the sometimes very 
low incidence of lymphocytes meant that traditional field 
of view quantification would not have as accurately reported 
cord inflammation. The mean cell count per section, per 
case, was plotted and represented by a single point on the 
scatter graphs and groups (F+, F−  SPMS and control), 
compared by Kruskal–Wallis test with Dunn’s multiple com-
parison posttest (see “Statistical analysis” and legends).
Quantification of axon loss
Digital images of heavy chain neurofilament H+ (by com-
bining antibodies SMI32 and RT97 to non-phosphorylated 
and phosphorylated epitopes, respectively) stained sections 
were used to calculate the number of axons in the anterior 
corticospinal tract, the lateral corticospinal tract and in the 
dorsal column from normal and demyelinated SPMS (see 
results for further information). Sections were scanned at 
200x magnification (Nikon Eclipse 80i microscope) and the 
reconstructed whole section images handled in Image-Pro 
Plus. Neurofilament H+ axons were counted automatically 
in the defined areas of interest following image thresholding 
to calculate axon density (neurofilament H+ axons/mm2) 
per region of interest per section, per cord level, per case. 
Relative axon loss was calculated by comparing axon density 
measures per SPMS case to the mean axon density value 
per region of interest in the control group.
Quantification of microglia-macrophages
The area of IBA-1+ immunoreactivity was quantified as 
an index of microglia/macrophage density in the spinal cord. 
One IBA-1/MOG double-labeled section per spinal cord 
level (3 levels), from each F+ SPMS, F− SPMS and control 
case, was analyzed. Double staining for MOG delineated 
the grey- white matter boundary, allowing a comparison 
between microglia/macrophage densities in these regions. 
Images captured at 40x magnification were manually outlined 
to highlight white and grey matter and the relative area 
of IBA-1+ immunoreactivity per area of white and grey 
matter, per spinal cord level, per case determined automati-
cally following image thresholding.
Statistical analysis
All data were assumed to be sampled from a non-Gaussian 
distribution and non-parametric analysis methods applied 
(44). The difference between two groups (for example, the 
density of axons in F+ SPMS vs. F− SPMS) was compared 
using the unpaired Mann-Whitney test, whilst Kruskal–Wallis 
test with Dunn’s multiple comparison posttest was used 
when comparing three or more groups (for example, when 
comparing the mean number of CD20+ cells per spinal 
meninges, between F+, F− SPMS and control. In this analysis 
each data point (n number) represents the mean number 
of cells from three sections, per cord level, per case). Spearman 
correlation was used to test for associations between groups 
and the Spearman r and P values reported in each instance. 
A two-sided P value  <  0.05 was considered significant 
(GraphPad PRISM v6).
RESULTS
We aimed to investigate the association between lymphoid-
like structures, B and T cell infiltrates, demyelination and 
axon loss in the spinal cord of  a cohort of  SPMS cases 
that had been categorized based on the presence (F+ SPMS) 
or absence (F−  SPMS) of  B cell rich lymphoid-like struc-
tures in the forebrain meninges (Figure  1A), to more fully 
understand the cellular mechanisms of  progressive 
disease.
Detection of lymphoid-like structures in the 
spinal cord meninges
Meningeal lymphoid-like structures with some of the features 
of tertiary lymphoid tissue were found in the spinal cord 
meninges of 3 out of the 11 F+  SPMS cases (MS79, MS92 
and MS234; Table  1). Lymphoid-like structures were identi-
fied in the presence of aggregates of CD20+ B cells, a 
reticulum of CD35+ follicular dendritic cells and by CD3+ 
and CD8+ T cells (Figure  1B–F). Lymphoid-like structures 
also contained immunoglobulin+ plasma cells (Figure  1G) 
and evidence of proliferating (Ki67+) B cells (Figure  1H). 
These structures were found at all examined levels of the 
cord, with no dorsal, lateral or ventral preference. More 
often, a variable extent of B cell infiltration was noted in 
the spinal meninges in both F+ and F−  SPMS cohorts 
(Figure  1I).
Perivascular and meningeal inflammation in the 
SPMS spinal cord
We quantified the extent of B cell infiltration in the spinal 
meninges and cord in F+  SPMS, F−  SPMS and controls. 
Numbers of B cells varied greatly between the meninges, 
Inflammation and spinal cord pathology in MSReali et al
Brain Pathology 0 (2020) 1–15
© 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
5
perivascular cuffs and tissue parenchyma (Figure  2A–D). 
There were more CD20+ B cells in the spinal meninges 
(cervical, thoracic and lumbar cord) of F+  SPMS in com-
parison to F−  SPMS and controls (F+  SPMS  =  79  ±  21, 
F−  SPMS  =  27  ±  17, Control  =  7  ±  2 mean cells/sec-
tion  ±  SEM, Figure  2E). The number of CD20+ cells was 
increased in perivascular cuffs of the white matter and in 
the tissue parenchyma of both white and grey matter, in 
F+  SPMS and F−  SPMS, in comparison to controls 
(Figure  2E). In summary, cases categorized as F+  SPMS 
based on the finding of lymphoid-like structures in the 
forebrain, were also the same cases that displayed elevated 
numbers of B cells in the spinal meninges [ie 9 of 11 cases 
of F+  SPMS had greater than the median number of 
B cells found in the SPMS spinal meninges (≥55 CD20+ 
cells; P  =  0.0019; when comparing the frequency of cases 
with greater than the median number of B cells in the F+ 
and F−  SPMS groups combined, Fisher’s exact test)].
CD4+ T cells were present as modest or sparse meningeal 
infiltrates (Figure  3A from a F+  SPMS case) and were 
sparsely distributed throughout the white and grey matter, 
both in the perivascular spaces and in the tissue (Figure 3B,C). 
CD4+ T cells were more numerous in F+  SPMS meninges, 
white and grey matter perivascular cuffs, in comparison to 
Figure 1. Characterization of ectopic lymphoid-like structures in post-
mortem spinal cord tissue from SPMS cases previously characterized in 
the presence (F+) or absence (F−) of lymphoid-like structures in the 
forebrain meninges (A). Immunostaining of serial spinal cord sections 
from an F+  SPMS case shows a meningeal lymphoid-like structure 
comprising a dense aggregate of CD20+ B cells (B), a reticulum of 
CD35+ fibers consistent with the presence of follicular dendritic cells 
(C), CD3 and CD8+ T cells (D–F) and plasma cells labeled with an anti-
Ig-G, -A, -M antibody (G). Proliferating B cells were identified by double 
immunofluorescence staining for CD20 (red) and Ki67 (green; H). 
CD20+ B cells were present in the meninges of F− SPMS cases but at 
lower densities and did not display any organised structure (I). Scale bar 
in B  =  50µm applies to all images.
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control tissue (Figure  3D). CD8+ T cells were also found 
in large numbers in the meninges of some SPMS cases and 
were typically found widely distributed throughout the white 
and grey matter of both F+  SPMS and F−  SPMS, and 
in greater numbers than seen for CD4+ T cells or CD20+ 
B cells (Figure  3E–H; mean number  ±  SEM meningeal 
CD8 in F+  SPMS  =  207  ±  34; CD4  =  89  ±  24; 
CD20  =  79  ±  21  cells/section). The approximate ratio of 
CD8:CD4:CD20 expressing cells was 2.5:1:1 and varied 
little between the different tissue compartments. Although 
the number of CD8+ T cells did not differ between F+ 
and F−  SPMS cohorts, there were more CD8+ cells in the 
F+  SPMS meninges in comparison to controls (P  <  0.05), 
and in F−  SPMS white and grey matter perivascular 
cuffs compared with control (P  <  0.05). There were 
also more CD8+ cells in grey matter parenchyma of 
F−  SPMS in comparison to control tissue (P  <  0.05, 
Figure  3H).
Figure 2. Quantifying meningeal, perivascular and parenchymal B cells 
in the spinal cord. Anti-CD20 immunohistochemistry revealed moderate 
(A) to mild (B) infiltrates of B cells in the spinal meninges, alongside 
small numbers in the perivascular space and tissue parenchyma (C, D). 
The number of CD20+ B cells was greater in the F+ SPMS meninges 
compared to the F− SPMS and controls (E). The number of B cells was 
also increased in comparison to controls in perivascular and parenchymal 
tissues. Values represent total CD20+ cells per section, from three 
sections per case with median and interquartile range indicated. 
Kruskal–Wallis and Dunn’s multiple comparison posttest. *P  <  0.05, 
**P  <  0.01. Scale bar: A, B  =  40  µm; C, D  =  30  µm. Ctrl, control; 
F+ SPMS, lymphoid-like structure positive SPMS; F− SPMS, lymphoid-
like structure negative SPMS.
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Quantification of demyelination and axonal loss 
in the SPMS spinal cord
We assessed the demyelination of the spinal cord by anti-MOG 
immunofluorescence across the sampled levels (Figure  4A–D). 
Total demyelinated lesion area per spinal cord ranged from 
zero to 74.5% of spinal cord cross-section area (F+  SPMS 
total section mean lesion area  =  39  ±  9%, 
F−  SPMS  =  17  ±  8%, P  =  0.061) with areas of subpial 
Figure 3. T cell infiltrates in the SPMS spinal cord. Immunohistochemical 
detection of CD4+ T cells in different compartments of the spinal cord 
of SPMS cases (A–C). The number of CD4+ T cells was greater in the 
meninges and in white and grey matter perivascular cuffs in F+ SPMS 
compared to controls (D). CD8+ T cells were occasionally seen as 
modest infiltrates in the meninges and at higher numbers than CD4+ T 
cells in perivascular spaces and parenchyma of the spinal cord white 
and grey matter (E–G). There was a large and variable extent of CD8+ 
infiltrates of the cord meninges, which differed between F+ SPMS and 
controls but not between F+ and F− SPMS (H). Scatter dot plot of total 
immunopositive cells per section, from three sections per case, with 
median and interquartile range indicated. Kruskal–Wallis and Dunn’s 
multiple comparison posttest. *P < 0.05. Scale bar: 40 µm. Ctrl, control; 
F+ SPMS, lymphoid-like structure positive SPMS; F− SPMS, lymphoid-
like structure negative SPMS.
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white matter and grey matter around the central canal fre-
quently affected. There was a trend toward a greater area of 
demyelinated white matter (36  ±  9%) and demyelinated grey 
matter (54  ±  13%) in F+  SPMS cases in comparison to 
F−  SPMS (white matter, 13  ±  6%, P  =  0.052; grey matter 
22 ± 10%, P = 0.056; Figure 4E). When comparing the lesion 
area at each of the three sampled levels of the spinal cord, 
there was a trend to increasing lesion area in white and grey 
matter regions in F+ compared to F−  SPMS (P  <  0.1), but 
this was only significantly different in the cervical white and 
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grey matter (white matter lesion area 44  ±  11% vs. 11  ±  6%, 
P  =  0.016; grey matter lesion area 66  ±  14% vs. 24  ±  11%, 
P  =  0.035; for F+ and F−  SPMS, respectively).
Axon damage and loss is a prominent pathological feature 
of  the MS spinal cord. We quantified the density of  neu-
rofilament-H+ axons in both motor (anterior corticospinal 
tract and lateral corticospinal tract) and sensory (dorsal 
column) tracts across all three spinal cord levels in F+, 
F−  SPMS and controls (Figure  4F, G). There was a reduc-
tion in the density of  axons in F+ SPMS relative to control 
axon density at all sampled levels (data not shown). The 
relative density of  axons in F−  SPMS did not differ to 
either group at any sampled level of  the spinal cord. When 
averaging the extent of  axon loss relative to control across 
the three areas, F+ SPMS (69 ± 4.6%) differed to F− SPMS 
(83  ±  2%, P  =  0.003) and to controls (100  ±  8.2%; 
P  <  0.0001; comparing control relative axon density to 
either F+  SPMS or F−  SPMS relative axon density; 
Figure  4F). There was a correlation between the extent of 
demyelination and the axon density in each tract across 
the sampled levels of  the SPMS cord (Figure 4H, P < 0.002 
in all comparisons). Correlations also existed in the sub-
analysis of  the F+ SPMS and F− SPMS cohorts (comparing 
percent white matter demyelination with the density of 
F+ SPMS ACST (r = −0.91, P = 0.005), LCST (r = −0.74, 
P  =  0.046) and DC axons (r  =  −0.86, P  =  0.01) and white 
matter demyelination with the density of  F−  SPMS ACST 
(r  =  −0.75, P  =  0.022), LCST (r  =  −0.86, P  =  0.004) and 
DC axons (r  =  −0.68, P  =  0.048; Spearman correlation 
analysis). Please note that there was no difference between 
the proportion of F+ and F− SPMS cases who experienced 
a spinal relapse (P  =  0.64, Fisher’s exact test), the total 
number of spinal relapses (P  =  0.32, Mann–Whitney test 
comparing the number of spinal relapses) or if  the spinal 
relapse was seen early (within 2  years of  diagnosis) or only 
later in disease (P  =  0.99, Fisher’s exact test).
Microglia and macrophages in the spinal white 
and grey matter
Microglial/macrophage activation was substantial in the 
demyelinated SPMS cord. IBA-1+ microglia/macrophages 
were present in large numbers in white and grey matter of 
F+ and F−  SPMS cases (Figure  5A–C), the majority of 
them with an activated morphology. The area of IBA-1+ 
immunoreactivity in white, grey and the total cord was 
greater in F+  SPMS cases in comparison to control 
(F+  SPMS white matter  =  25  ±  4%, ctrl  =  11  ±  2%, 
P  =  0.03; F+  SPMS GM  =  29  ±  6%, ctrl  =  11  ±  1%, 
P = 0.04; F+ SPMS total section = 26 ± 3%, ctrl = 11 ± 2%, 
P = 0.008) but was not different between F+ and F− SPMS, 
or between F−  SPMS and control (Figure  5D).
B cell infiltration in the meninges correlates 
with the extent of spinal cord pathology
We next investigated the interrelationship between the density 
of B and T cells with meningeal and perivascular inflamma-
tion of the underlying white matter (Table 3), with the extent 
of demyelination (Table  4) and relative axonal loss (Table  5). 
The correlation matrices demonstrate the statistically significant 
relationships found between the densities of the different 
lymphocyte populations quantified in the meninges and high-
light the close association seen between meningeal inflamma-
tion (CD4, CD8 and CD20+ cells) and the perivascular 
lymphocytic infiltrates of the white matter. Correlation analysis 
of the SPMS groups revealed that it was only in the F+ SPMS 
cohort that the density of meningeal B cells correlated mod-
estly (r = 0.684) with the extent of white matter demyelination 
(Table  4). The density of meningeal B cells in F+  SPMS 
also correlated with the extent of axon loss in the lateral 
corticospinal tract, dorsal column and combined spinal cord 
tracts axons (Table  5). The density of CD4 and CD8 cells 
did not correlate with the extent of demyelination or axon 
loss in F+ SPMS. The same pathological relationships between 
the number of meningeal B cells and demyelination and 
axonal loss were not evident in the F−  SPMS cases, sug-
gesting a less prominent role for B cell immunity in these 
cases (Tables  3–5). Previous work has reported a correlation 
between the density of CD3 meningeal infiltrates and axon 
loss (2). In our study, the sum of both CD4+ and CD8+ 
cells in all cases of SPMS was modestly correlated with axon 
loss (spearman r  =  −0.372, P  =  0.0328), but this correlation 
did not exist in the separate F+ or F−  SPMS groups.
DISCUSSION
It is now well established that leptomeningeal inflammation 
is a prominent feature of cortical pathology and strongly 
Figure 4. Demyelination and axon loss in the SPMS cord. Anti-MOG 
immunostaining revealed the variable extent of demyelination in the F+ 
and F−  SPMS spinal cord. Multiple discrete white and grey matter 
lesions or extensive confluent demyelination was seen in F+  SPMS, 
whereas lesions tended to be smaller in the F−  SPMS cord (A–C; 
arrows). MOG+ myelin in a control case for comparison (D). The 
percentage of total (Tot), white matter (WM) and grey matter (GM) 
demyelination showed a trend to being greater in the F+ SPMS cohort 
in comparison to the F− SPMS cases (E). Axon density was determined 
by quantifying the number of neurofilament H+ (NFil) structures in the 
anterior (a) and lateral (b) corticospinal tracts (CST) and the dorsal 
column (c; F, G). Axon density relative to control counts were compared 
for each tract across the three sampled levels (cervical, thoracic and 
lumber cord) and expressed as percent axon loss. Axon density (%) was 
reduced in comparison to control axon counts in F+ SPMS cases at all 
sampled levels of the cord. Total axon count correlated with the relative 
area of white matter demyelination in F+  SPMS (P  <  0.002 for each 
comparison; H). Box-and-whiskers plot showing the mean (+), median 
(line), interquartile range (box) and 5-95 percentiles (whiskers) for each 
group. Differences between groups were tested by (E) the non-
parametric Mann-Whitney test or (F) Kruskal–Wallis and Dunn’s multiple 
comparison posttest. *P  <  0.05, **P  <  0.01. Correlation analysis by 
Spearman comparison. Scale bars (A–D, G) = 1 mm, inset 40 µm. Ctrl, 
control; F+, lymphoid-like structure positive SPMS; F−, lymphoid-like 
structure negative SPMS.
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associates with the extent of subpial neocortical grey matter 
demyelination, microglial activation and neuronal loss in a 
substantial proportion of acute and progressive MS cases 
at post-mortem (6,24,35,39). Here, we report that spinal 
cord pathology is also more severe in SPMS cases charac-
terized by elevated leptomeningeal inflammation of the 
forebrain. The more severe cord pathology was characterized 
by a greater degree of lymphocyte infiltration of the spinal 
leptomeninges, perivascular spaces and parenchyma, micro-
glial activation and axonal loss, which correlated with the 
density of B cell, but not T cell, infiltrates in the spinal 
meninges. This work adds to our knowledge of the impor-
tance of CNS-resident B cells to the pathology of 
progressive disease and furthers our understanding of the 
importance of the compartmentalized meningeal inflamma-
tory response to tissue damage in progressive MS.
Meningeal inflammation and lymphoid-like 
structures are widespread and not only 
restricted to the brain meninges in progressive 
MS
Screening of three spinal segments per case, representing 
cervical, thoracic and lumbar cord, revealed that three out 
of the 11 MS cases that were characterized by lymphoid-
like structures in the cerebral meninges had similar structures 
Figure 5. Microglia/macrophage activation in the SPMS cord. Example 
of demyelination in the case of F+ SPMS (A). Large numbers of IBA-1+ 
microglia/macrophages (green) were present in the white matter 
parenchyma (B) and, although lower in number, in the grey matter 
(C; IBA-1+ cells and neurofilament-H+ neurons/neurites). The relative 
area of anti-IBA-1 immunoreactivity was increased in F+  SPMS in 
comparison to controls but was not different between F+ and F− SPMS 
cases (D). Data plotted as the box-and-whiskers plot showing the mean 
(+), median (line), interquartile range (box) and 5-95 percentiles 
(whiskers) and compared by Kruskal–Wallis and Dunn’s multiple 
comparison posttest. *P < 0.01. Scale bars: A = 1mm B, C = 40µm. Ctrl, 
control; F+, lymphoid-like structure positive SPMS; F−, lymphoid-like 
structure negative SPMS.
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in the spinal cord meninges. In the brain, where we first 
observed lymphoid-like structures, it was often necessary to 
screen twelve or more blocks of cortical/subcortical tissue 
before such infiltrates were noted, with 5-67% of the tissue 
blocks screened per case found to contain lymphoid-like 
structures (1,24). Therefore, it is likely that a more extensive 
screening along the entire length of the cord might have 
revealed more cases with evidence of lymphoid-like struc-
tures. However, the F+  SPMS cases in which we did not 
find lymphoid-like structures in the spinal cord still exhibited 
extensive meningeal inflammation, including the presence of 
immune cell aggregates rich in B cells. The fact that the 
immune cells in the cord meninges were not always organ-
ized into lymphoid-like structures may reflect the different 
anatomical structure (only a single sulcus at the anterior 
median fissure) of the spinal cord, which may not be as 
conducive to the accumulation of large and organized immune 
cell infiltrates. Large, organized lymphoid-like structures were 
also not seen in the cerebellum, a structure with very limited 
sulcal volume, and where, as in this study, increased menin-
geal inflammation associated with a more severe subpial 
pathology (25).
Meningeal inflammation is associated with 
elevated myelin and axonal pathology
The current study suggests that the presence of lymphoid-
like structures in the forebrain signifies a globally elevated 
inflammatory pathology, as SPMS cases with lymphoid-like 
structures in the brain showed extensive demyelination and 
axonal loss in the spinal cord. The extensive demyelination 
Table 3. Meningeal inflammation and tissue infiltrates.
  Meninges Perivascular white matter
CD8 CD4 Total CD20 CD8 CD4 Total
CD20 r = 0.356 
P = 0.176
r = 0.559 
P = 0.027
r = 0.677 
P = 0.005
r = 0.585 
P = 0.005
r = 0.047 
P = 0.865
r = 0.532 
P = 0.036
r = 0.462 
P = 0.074
CD8 – r = 0.620 
P = 0.009
r = 0.875 
P < 0.000
r = 0.368 
P = 0.147
r = 0.549 
P = 0.024
r = 0.588 
P = 0.015
r = 0.60 
P = 0.013
CD4 – – r = 0.826 
P < 0.000
r = 0.574 
P = 0.018
r = 0.022 
P = 0.936
r = 0.821 
P < 0.001
r = 0.547 
P = 0.025
Correlating meningeal B cells and T cells with inflammation in the spinal meninges and perivascular space. Total refers to the sum of CD20, CD4 and 
CD8+ cells. Spearman r and P values reported. Significant correlations highlighted.
Table 4. Meningeal inflammation and spinal cord demyelination in F+ SPMS.
    White matter lesion area Grey matter lesion area Total lesion area
F+ SPMS CD20 r = −0.684 P = 0.034 r = −0.539 P = 0.114 r = −0.685 P = 0.035
CD8 r = 0.143 P = 0.752 r = −0.132 P = 0.736 r = 0.048 P = 0.935
CD4 r = 0.191 P = 0.665 r = 0.168 P = 0.693 r = −0.037 P = 0.930
Total r = 0.143 P = 0.752 r = 0.144 P = 0.736 r = 0.071 P = 0.882
F− SPMS CD20 r = 0.349 P = 0.323 r = 0.325 P = 0.360 r = 0.249 P = 0.484
CD8 r = 0.659 P = 0.092 r = 0.756 P = 0.041 r = 0.611 P = 0.118
CD4 r = 0.366 P = 0.379 r = 0.146 P = 0.743 r = 0.144 P = 0.736
Total r = 0.658 P = 0.092 r = 0.659 P = 0.093 r = 0.539 P = 0.176
Correlating B cells and T cells with demyelination. Total refers to the sum of all lymphocytes. F+ SPMS = lymphoid-like structure positive secondary 
progressive multiple sclerosis; F− SPMS = lymphoid-like structure negative secondary progressive multiple sclerosis. Spearman r and P values re-
ported. Significant correlations highlighted.
Table 5. Meningeal B cells and axon loss in F+ SPMS.
    A CST L CST D Col All tracts
F+ SPMS CD20 r = 0.714 
P = 0.136
r = 0.893 
P = 0.012
r = 0.886 
P = 0.033
r = 0.684 
P < 0.001
CD8 r = 0.172 
P = 0.782
r = 0.801 
P = 0.098
r = −0.420 
P = 0.482
r = 0.035 
P = 0.903
CD4 r = −0.208 
P = 0.737
r = 0.439 
P = 0.193
r = −0.542 
P = 0.346
r = −0.189 
P = 0.499
Total r = 0.119 
P = 0.848
r = 0.762 
P = 0.134
r = −0.357 
P = 0.555
r = 0.120 
P = 0.680
F− SPMS CD20 r = −0.029 
P > 0.999
r = −0.028 
P = 0.989
r = 0.046 
P = 0.931
r = −0.066 
P = 0.795
CD8 r = −0.429 
P = 0.419
r = −0.371 
P = 0.497
r = −0.370 
P = 0.470
r = −0.179 
P = 0.478
CD4 r = −0.543 
P = 0.297
r = −0.314 
P = 0.564
r = −0.553 
P = 0.255
r = −0.379 
P = 0.121
Total r = −0.314 
P = 0.564
r = −0.486 
P = 0.356
r = −0.423 
P = 0.398
r = −0.166 
P = 0.510
Correlating B cells, T cell and total B and T cells with axon loss in the 
anterior corticospinal tract (A CST), lateral corticospinal tract (L CST), 
dorsal column (D Col) or with the mean axon loss across all assessed 
tracts. F+ SPMS = lymphoid-like structure positive secondary progres-
sive multiple sclerosis; F− SPMS = lymphoid-like structure negative sec-
ondary progressive multiple sclerosis. Spearman r and P values 
reported. Significant correlations highlighted.
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and axon loss in the cord is in line with that reported by 
others (14,19,48). Demyelination was highly variable and 
was not different between F+  SPMS and F−  SPMS cases 
(which is likely to be the result of the relatively small num-
ber of cases being studied, due to the limited available 
spinal cord from these previously characterized cases). Of 
note, and evident in both SPMS cohorts, was the finding 
that the demyelinated spinal grey matter covered a greater 
area than the demyelinated white matter in the same case. 
These findings suggest that immune-mediated damage arising 
from the overlying meninges is only one component of the 
pathogenetic mechanisms, and that other local and distal 
indirect contributions from cells in the parenchyma also 
contribute to lesion development and expansion. Our data 
also shows that it is not only subpial grey matter lesions 
which can topographically associate with meningeal inflam-
mation and supports previous neuroimaging descriptions of 
gradients of white, as well as GM pathology, greatest near 
the brain’s surfaces, in the central white and grey matter 
areas (8,41,51). It would be interesting to determine if  gra-
dients of spinal cord tissue damage exist in the subpial 
white matter or in the grey matter away from the central 
canal.
Axonal damage is a major contributor to clinical progres-
sion in MS (7,33,48,56). Our finding of an increased axon 
loss in F+ compared to F−  SPMS cases most likely reflects 
the increased meningeal and parenchymal inflammation and 
demyelination in this group of patients. Myelin loss strips 
axons of crucial metabolic and structural support, and 
increased inflammation, be it focal inflammatory infiltrates 
or more diffuse inflammation of the tissue parenchyma and 
meninges, will sustain a neurotoxic and damaging environ-
ment (17,46,55). Axon loss in the spinal cord does not 
associate with the spinal cord cross-sectional area (48). This 
finding indicates caution when interpreting magnetic reso-
nance imaging measures of cord atrophy as a surrogate for 
neuroaxonal loss in the patient. A potential component of 
this dissociation between axon density and cord cross- 
sectional area will include cellular infiltration and tissue 
inflammation, reactive microglial and astrogliosis, which are 
likely to be quite extensive in cases harboring lymphoid-like 
structures. By improving our understanding of the associa-
tions that exist between meningeal inflammation and spinal 
cord tissue pathology in some cases might help in the inter-
pretation of new and powerful in vivo imaging technologies 
(21,53).
B cells and not T cells are most strongly 
associated with spinal cord pathology
The only immune cell component of the cord meninges 
that was consistently different between the F+ and F− SPMS 
groups was the number of CD20+ B cells, which were 
3-fold higher in number in the F+ SPMS cases. The density 
of CD8+ T cells was greater than that of CD4+ T cells 
in all measured compartments, in line with previous findings 
(2,12). However, the number of CD8 and CD4+ T cells 
varied considerably and did not differ between F+ and 
F−  SPMS groups.
It has been shown previously that the density of menin-
geal CD3+ T cells correlated with axon loss in the normal-
appearing cervical spinal cord (2), whilst the number of 
CD8+ T cells correlated with a loss of small caliber axons 
in the lumbar-sacral cord (12). Whilst neither the number 
of CD4+ or CD8+ T cells correlated with axon loss in 
our study, we saw a significant association between the total 
number of T cells (the sum of CD4 and CD8 cell densi-
ties) and axon loss, which supports the work of others. 
This modest correlation did not exist in our subgroup 
analysis, where it was only the density of CD20+ B cells 
in the F+  SPMS cohort that associated with measures of 
parenchymal pathology (see Figure  6).
In F+  SPMS, CD20+ B cells were often found as aggre-
gates in the spinal cord meninges, which associated with 
increased numbers of CD4+ T cells in the meninges and 
perivascular spaces and with increased numbers of activated 
microglia/macrophages, and increased demyelination and 
axon loss (Tables  3–5 and Figure  6). Activated memory 
B cell subsets from MS can be stimulated to secrete elevated 
levels of TNF, LTα, IL6 and GM-CSF, and are highly 
effective antigen-presenting cells, both in the inflamed organ 
and draining lymph tissues (29). GM-CSF secreted by 
B cells activates myeloid cells that worsen experimental 
disease, whilst GM-CSF and IL6 secreting B cells are more 
abundant in MS and are at least in part ablated by anti-B 
cell therapy and indicate a successful response to therapy 
(5,30). New, emerging B cells, which repopulate the immune 
system following anti-CD20 treatment, lack such a pro-
inflammatory profile (15,30). Ex-vivo activation of B cells 
stimulates CD4 and CD8 proliferation and pro-inflammatory 
activation, whilst B cell depletion diminishes the capacity 
of CD4+ cells from MS patients to be stimulated through 
an MHC II/HLA-DR15 B cell-to- CD4+ T cell interaction 
Figure 6. The main findings of this study are highlighted. Meningeal 
inflammation and particularly B cell inflammation (red circles), is 
associated with greater CD4+ T cell (blue circles) and B cells in the 
connective tissue and cord parenchyma. CD20+ B cell density of the 
meninges also correlated with the extent of underlying white matter 
demyelination (blue sector) and axon loss (red sector). These correlations 
only existed in the F+ SPMS cohort characterized in the presence of 
lymphoid-like structures in the forebrain meninges.
Inflammation and spinal cord pathology in MSReali et al
Brain Pathology 0 (2020) 1–15
© 2020 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology
13
(4,26,42). These stimulated effector CD4+ cells have CNS-
homing and auto-reactive phenotype to antigens expressed 
in the MS neocortex (26). Genetic factors impact the risk 
of MS but their relative contribution to disease outcome 
is still to be defined. HLA-DR15 status is the principal 
genetic susceptibility locus for MS, whilst also being associ-
ated with elevated forebrain and spinal cord pathology, albeit 
more strongly linked to T cell, rather than B cell, inflam-
mation (12-13,58). Alongside a central role in antigen pres-
entation and T cell activation, effector memory B cells from 
MS patients can directly induce oligodendrocyte and neu-
roaxonal injury in vitro (31,32) and suggests that ablating 
this B cell central memory pool could be important in 
mediating a disease-modifying effect (3).
We suggest that a higher level of  demyelination and 
axonal loss in MS cases expressing meningeal lymphoid-like 
structures may in part be related to the increased immune 
cell infiltration in the cord meninges, which via the produc-
tion of pro-inflammatory cytokines and chemokines, includ-
ing TNF, IL6, IFNγ and CXCL13, could cause direct and/
or indirect damage to the underlying tissues (18,28,37,38). 
This inflammatory milieu is reflected in the CSF (27) and 
a small number of inflammatory mediators, including B 
cell chemokines, define both a post-mortem and a clinical 
cohort with a higher lesion load and poor prognosis (38). 
Since CSF circulates through the ventricles, over the brain 
and in and over the cord, our results reinforce the idea 
that an inflammatory milieu present throughout the CSF 
space in a large proportion of MS cases from early stages 
and during the progressive phase, could lead to diffuse 
tissue inflammation, activation of astroglia and disruption 
of the glial limiting barriers of  the pia and parenchyma.
Limitations of this study
The current study has involved a small number of cord 
samples, which was due to the limited availability of appro-
priate samples from previously characterized cases of F+ 
and F−  SPMS. The relative infrequent finding of bona fide 
lymphoid-like structures may well reflect the need to screen 
more extensively along the length of the cord to better 
understand the extent of the spinal leptomeningeal inflam-
mation. We did not quantify the density of macrophages 
or plasma cells in this study, cells which are found at elevated 
numbers in cases that follow an active progressive disease 
(17,24,36) and may also associate with the compartmental-
ized immune response and topographically with subpial 
pathology in other brain areas (28). No association was 
seen between F+ status and the incidence of spinal relapses. 
Although documentation of relapses is unreliable (50), the 
UK MS Tissue Bank reports include general practitioner 
and/or hospital recorded relapses.
CONCLUSIONS
The extent of spinal cord atrophy and demyelination is an 
early clinical and imaging prognostic of risk to clinically 
definite MS and of later disease severity (9,47). For these 
reasons we need to know more about mechanisms that 
contribute to the damage of the spinal cord if  we are to 
identify surrogate fluid markers or to further our under-
standing to aid the development of imaging technologies. 
In this report, we further corroborate the hypothesis that 
B cells play a key role in MS pathology and highlight the 
association between B cell inflammation in the forebrain 
and that seen in the spinal cord and between B cell inflam-
mation of the spinal meninges and lymphocyte infiltrates, 
demyelination and axon loss in clinically eloquent 
pathways.
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